Search Within

Mikhail Roshal

  1. "Biostatistics Service"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (22)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Biostatistics Service (53)
  2. Department of Pathology and Laboratory Medicine (53)
  3. Epidemiology and Biostatistics (53)
  4. Center for Hematologic Malignancies (52)
  5. Department of Medicine (51)
  6. Hematologic Malignancies, Division of (51)

More Groups

People
  1. Sean Devlin (31)
  2. Sergio Giralt (30)
  3. Maria Arcila (24)
  4. Andriy Derkach (21)
  5. Ahmet Dogan (20)
  6. Martin Tallman (18)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (6)
  4. 2022 (6)
  5. 2021 (13)
  6. 2020 (8)

More Years

Publications
  1. Blood (21)
  2. Blood Advances (6)
  3. American Journal of Hematology (3)
  4. Leukemia and Lymphoma (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. Elsevier Inc. (4)
  3. John Wiley & Sons, Inc. (3)
  4. Nature Publishing Group (3)
  5. Taylor & Francis Group (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Double unit cord blood transplantation compares favorably to T-cell depleted matched adult donor transplantation for the treatment of acute leukemia due to a robust protection against relapse
    Meeting Abstract

    Politikos, I.; Flynn, J.; Devlin, S. M.; Fingrut, W.; Maloy, M. A.; Naputo, K.; Chinapen, S.; Rodriguez, N. T.; Quach, S.; Dominguez, Y.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
    Journal Article

    Ramaswamy, K.; Steinherz, P. G.; Agrawal, A. K.; Forlenza, C. J.; Mauguen, A.; Roshal, M.; Trippett, T.; Kernan, N. A.; Sulis, M. L.; Shukla, N.
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Reduced plasmacytoid dendritic cell output is associated with high risk in low-grade myelodysplastic syndrome
    Research Letter

    Chan, A.; Liu, Y.; Devlin, S.; Gao, Q.; Baik, J.; Sigler, A.; Londono, D.; Arcila, M.; Levine, R.; Dogan, A.; more...
    HemaSphere (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of secondary acute myeloid leukemia with mixed phenotype
    Meeting Abstract

    Galera, P.; Chan, A.; Derkach, A.; Liu, Y.; Baik, J.; Famulare, C.; Sigler, A.; Arcila, M. E.; Mata, D. A.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save